Furthermore, although no significant increases in the glycolysis regulator PFKFB3 nor in antioxidant genes such as PRDX3 could be observed in the carcinoma group, the observed differences in the ratios of PFKFB3/PRDX3 and PFKFB3/PGC1A might be functionally relevant, stressing the reduction in PGC-1α activity, and possibly in the antioxidant capacity in carcinoma patients. The gene discussed is PPARGC1A; the disease is carcinoma.